|
Bukowski, R M; Olencki, T; Gunn, H et al. (1996) Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings. Clin Cancer Res 2:347-57
|
|
Bukowski, R M; Murthy, S A; Finke, J et al. (1994) Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects. J Immunother Emphasis Tumor Immunol 15:273-82
|
|
Bukowski, R M; Budd, G T; Gibbons, J A et al. (1994) Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 12:97-106
|
|
Bukowski, R M; Murthy, S; McLain, D et al. (1993) Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects. J Immunother Emphasis Tumor Immunol 13:267-74
|
|
Thomassen, M J; Antal, J M; Connors, M J et al. (1993) Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes. J Immunother Emphasis Tumor Immunol 14:43-50
|
|
Thomassen, M J; Ahmad, M; Barna, B P et al. (1991) Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 51:857-62
|
|
Bukowski, R M; Sharfman, W; Murthy, S et al. (1991) Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 51:4199-205
|
|
Caulfield, M J; Barna, B; Murthy, S et al. (1990) Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma. J Biol Response Mod 9:319-28
|
